Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 17
HOS-086267 · Präparat HOS-083284
Bedaquiline No interaction study is available with ritonavir only. In an interaction study of
single-dose bedaquiline and multiple dose lopinavir/ritonavir, the AUC of
bedaquiline was increased by 22%. This increase is likely due to ritonavir and a
more pronounced effect may be observed during prolonged co-administration. Due
to the risk of bedaquiline related adverse events, co-administration should be
avoided. If the benefit outweighs the risk, co-administration of bedaquiline with
ritonavir must be done with caution. More frequent electrocardiogram monitoring
and monitoring of transaminases is recommended (see section 4.4 and refer to the
bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) bedaquiline (HOS-086268)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 13fd00e555c9ee84479a09bd0b5efb043b6c724aac394be9d70ecfdae9c81259 · Zeichen 32476–33474 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50
HOS-086450 · Präparat HOS-083284
49
Ritonavir effects on Non-antiretroviral Co-administered Medicinal Products
Co-administered Medicinal Products Dose of Co-administered Medicinal Dose of Effect on Co- Effect on Co-
Products (mg) NORVIR administered administered
(mg) Medicinal Medicinal
Products Products Cmax
AUC
Bedaquiline No interaction study is available with ritonavir only. In an interaction study of single-dose
bedaquiline and multiple dose lopinavir/ritonavir, the AUC of bedaquiline was increased
by 22%. This increase is likely due to ritonavir and a more pronounced effect may be
observed during prolonged co-administration. Due to the risk of bedaquiline related
adverse events, co-administration should be avoided. If the benefit outweighs the risk,
co-administration of bedaquiline with ritonavir must be done with caution. More frequent
electrocardiogram monitoring and monitoring of transaminases is recommended (see
section 4.4 and refer to the bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) bedaquiline (HOS-086268)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 31738bbc16b4c93df384898192dda583972908126d2b2e301991a8d91064b893 · Zeichen 33608–35264 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 17–18
HOS-108900 · Präparat HOS-093083
17
Anti-gout agents
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg twice Cmax: ↑ 1.8-fold with renal and/or hepatic
daily) Due to P-gp and/or CYP3A4 impairment is contraindicated due
inhibition by ritonavir. to a potential increase of
colchicine-related serious and/or
life-threatening reactions such as
neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3
and 4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is
recommended in patients with
normal renal or hepatic function if
treatment with Kaletra is required.
Refer to colchicine prescribing
information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased
risk of adverse events related to
fusidic acid, notably
rhabdomyolysis (see section 4.3).
When used for osteo-articular
infections, where the co-
administration is unavoidable,
close clinical monitoring for
muscular adverse events is
strongly recommended (see section
4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline
(single dose) AUC: ↑ 22% related adverse events, the
Cmax: ↔ combination of bedaquiline and
(Lopinavir/ritonavir Kaletra should be avoided. If the
400/100 mg BID, multiple A more pronounced effect on benefit outweighs the risk,
dose) bedaquiline plasma exposures co-administration of bedaquiline
may be observed during with Kaletra must be done with
prolonged co-administration with caution. More frequent
lopinavir/ritonavir. electrocardiogram monitoring and
monitoring of transaminases is
CYP3A4 inhibition likely due to recommended (see section 4.4 and
lopinavir/ritonavir. refer to the bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146) bedaquiline (HOS-086268) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f0063cdfed3d4b44f9ebbe33645572935b60d76cab70c9d2b49e5bc05279da2c · Zeichen 30589–35272 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 53–54
HOS-109013 · Präparat HOS-093083
53
benefit/risk to patient justifies the use
of voriconazole.
Anti-gout agents
Colchicine single dose Colchicine: Concomitant administration of
AUC: ↑ 3-fold Kaletra with colchicine in patients
(Ritonavir 200 mg Cmax: ↑ 1.8-fold with renal and/or hepatic impairment
twice-daily) Due to P-gp and/or CYP3A4 is contraindicated due to a potential
inhibition by ritonavir. increase of colchicine-related serious
and/or life-threatening reactions such
as neuromuscular toxicity (including
rhabdomyolysis) (see sections 4.3 and
4.4). A reduction in colchicine
dosage or an interruption of
colchicine treatment is recommended
in patients with normal renal or
hepatic function if treatment with
Kaletra is required. Refer to
colchicine prescribing information.
Antihistamines
Astemizole Serum concentrations may be Concomitant administration of
Terfenadine increased due to CYP3A Kaletra and astemizole and
inhibition by lopinavir/ritonavir. terfenadine is contraindicated as it
may increase the risk of serious
arrhythmias from these agents (see
section 4.3).
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased risk
of adverse events related to fusidic
acid, notably rhabdomyolysis (see
section 4.3). When used for osteo-
articular infections, where the co-
administration is unavoidable, close
clinical monitoring for muscular
adverse events is strongly
recommended (see section 4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline related
(single dose) AUC: ↑ 22% adverse events, the combination of
Cmax: ↔ bedaquiline and Kaletra should be
(Lopinavir/ritonavir avoided. If the benefit outweighs the
400/100 mg BID, A more pronounced effect on risk, co-administration of bedaquiline
multiple dose) bedaquiline plasma exposures with Kaletra must be done with
may be observed during caution. More frequent
prolonged co-administration with electrocardiogram monitoring and
lopinavir/ritonavir. monitoring of transaminases is
recommended (see section 4.4 and
CYP3A4 inhibition likely due to refer to the bedaquiline SmPC).
lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146) bedaquiline (HOS-086268) voriconazole (HOS-084524) colchicine (HOS-086147) astemizole (HOS-085608) terfenadine (HOS-085607)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage cad5366a6fb47c00b40c65b02f661a2f3f24b27d6187e7ce6cfffb83a5f12fd8 · Zeichen 29746–34245 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 89–90
HOS-109089 · Präparat HOS-093083
89
Anti-infectives
Fusidic acid Fusidic acid: Concomitant administration of
Concentrations may be increased Kaletra with fusidic acid is contra-
due to CYP3A inhibition by indicated in dermatological
lopinavir/ritonavir. indications due to the increased risk
of adverse events related to fusidic
acid, notably rhabdomyolysis (see
section 4.3). When used for osteo-
articular infections, where the co-
administration is unavoidable, close
clinical monitoring for muscular
adverse events is strongly
recommended (see section 4.4).
Antimycobacterials
Bedaquiline Bedaquiline: Due to the risk of bedaquiline
(single dose) AUC: ↑ 22% related adverse events, the
Cmax: ↔ combination of bedaquiline and
(Lopinavir/ritonavir Kaletra should be avoided. If the
400/100 mg BID, A more pronounced effect on benefit outweighs the risk,
multiple dose) bedaquiline plasma exposures co-administration of bedaquiline
may be observed during with Kaletra must be done with
prolonged co-administration with caution. More frequent
lopinavir/ritonavir. electrocardiogram monitoring and
monitoring of transaminases is
CYP3A4 inhibition likely due to recommended (see section 4.4 and
lopinavir/ritonavir. refer to the bedaquiline SmPC).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fusidic acid (HOS-086146) bedaquiline (HOS-086268)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 65e6870b925cfa041fafca521b5fcbe7c52c38b5b0bbc4488f37222ae0fa46b7 · Zeichen 32216–34417 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.